Telix Pharmaceuticals Valuation
| TLX Stock | 18.36 0.12 0.66% |
At this time, the company appears to be fairly valued. Telix Pharmaceuticals has a current Real Value of USD17.69 per share. The regular price of the company is USD18.36. Our model measures the value of Telix Pharmaceuticals from inspecting the company fundamentals such as Shares Outstanding of 334.72 M, operating margin of 0.09 %, and Return On Equity of 0.2 as well as reviewing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Telix Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Telix Pharmaceuticals is based on 3 months time horizon. Increasing Telix Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Telix Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Telix Stock. However, Telix Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 18.36 | Real 17.69 | Hype 18.36 | Naive 18.39 |
The intrinsic value of Telix Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Telix Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Telix Pharmaceuticals Limited helps investors to forecast how Telix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Telix Pharmaceuticals more accurately as focusing exclusively on Telix Pharmaceuticals' fundamentals will not take into account other important factors: Telix Pharmaceuticals Total Value Analysis
Telix Pharmaceuticals Limited is at this time expected to have company total value of 5.2 B with market capitalization of 5.23 B, debt of 581.45 M, and cash on hands of . Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Telix Pharmaceuticals fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.2 B | 5.23 B | 581.45 M |
Telix Pharmaceuticals Investor Information
The company had not issued any dividends in recent years. Telix Pharmaceuticals had 1:1000 split on the 29th of October 2013. Based on the key indicators related to Telix Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Telix Pharmaceuticals Limited is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Telix Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Telix Pharmaceuticals has an asset utilization ratio of 51.65 percent. This suggests that the Company is making USD0.52 for each dollar of assets. An increasing asset utilization means that Telix Pharmaceuticals Limited is more efficient with each dollar of assets it utilizes for everyday operations.Telix Pharmaceuticals Profitability Analysis
The company reported the last year's revenue of 783.21 M. Total Income to common stockholders was 49.92 M with profit before taxes, overhead, and interest of 405.35 M.About Telix Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Telix Pharmaceuticals. We calculate exposure to Telix Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Telix Pharmaceuticals's related companies.Telix Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 334.7 M | |
| Forward Price Earnings | 77.5194 |
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.